Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of neoantigens in oesophageal adenocarcinoma

ABSTRACT: We present data from tissues of seven oesophageal adenocarcinomas of CD4 and CD8 T cell epitopes eluted from the cell surface using mass spectrometry (immunopeptidomics) of presented HLA bound peptides.This dataset forms part of the publication:Nicholas, B., Bailey, A., McCann, K.J., Wood, O., Walker, R.C., Parker, R., Ternette, N., Elliott, T., Underwood, T.J., Johnson, P. and Skipp, P. (2022), Identification of neoantigens in esophageal adenocarcinoma. Immunology. Accepted Author Manuscript. https://doi.org/10.1111/imm.13578

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Esophageal Epithelium

DISEASE(S): Esophageal Cancer

SUBMITTER: Alistair Bailey

LAB HEAD: Paul J Skipp

PROVIDER: PXD031108 | Pride | 2022-09-27

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	BLN_130519_MHC1IPUnder_711-16_T_Even1.mgf	Mgf
	BLN_130519_MHC1IPUnder_711-16_T_Even2.mgf	Mgf
	BLN_130519_MHC1IPUnder_711-16_T_Odd1.mgf	Mgf
	BLN_130519_MHC1IPUnder_711-16_T_Odd2.mgf	Mgf
	BLN_130519_MHC1IPUnder_716-16_T_Even1.mgf	Mgf

Items per page:

1 - 5 of 149

Similar Datasets

Identification of sensitiser modified HLA-peptides presented by keratinocytes

Project description:Skin sensitisation following the covalent modification of proteins by low molecular weight chemicals (haptenation) is mediated by cytotoxic T lymphocyte (CTL) recognition of human leukocyte antigen molecules (HLA) presented on the surface of almost all nucleated cells. There are three nonmutually exclusive models for how haptens mediate CTL recognition: direct stimulation by haptenated peptides; hapten modification of HLA leading to an altered HLA-peptide repertoire; or a hapten altered proteome leading to an an altered HLA-peptide repertoire. To address the mechanism in skin, we set out to utilise proteomic analysis of keratinocyte presented antigens following exposure to 2,4-dinitrochlorobenzene (DNCB). We show that following DNCB exposure, cultured keratinocytes present cysteine haptenated (dinitrophenylated) peptides in multiple HLA molecules. In addition, we find that one of the DNCB modified peptides derives from the active site of cytosolic glutathione-S transferase-ω. These results provide support for the hypothesis that a key mechanism of skin sensitisation is stimulation of CTLs by haptenated peptides.

2021-01-04 | PXD021373 | Pride

Extending the Mass Spectrometry-Detectable Landscape of the Immunopeptidome by use of Restricted access Material

Project description:Mass spectrometry-based immunopeptidomics enables the comprehensive identification of major histocompatibility complex (MHC) peptides from cell culture as well as from tissue or tumor samples and is increasingly applied for the identification of tumor-specific and viral T-cell epitopes. Although mass spectrometry is generally accounted as an unbiased method for MHC peptide identification, the physicochemical properties of MHC peptides can greatly influence their detectability. For instance, highly hydrophobic peptides get easily lost already during sample preparation when C18 solid phase extraction (SPE) is used for separating MHC peptides from proteins. To overcome this limitation, we established an optimized protocol for this sample preparation step applying restricted access material (RAM). Compared to C18-SPE, RAM-SPE improves the overall MHC peptide recovery and extends the landscape of mass spectrometry-detectable MHC peptides towards more hydrophobic peptides.

2022-11-07 | PXD034017 | Pride

Isolation of mouse and human MHC class I- and II-associated peptides for the analysis of immunopeptidomes by mass spectrometry

Project description:Immunopeptidomics is an emerging field that fuels and guides the development of vaccines and immunotherapies. More specifically, it refers to the science of investigating the composition of peptides presented by major histocompatibility complex (MHC) class I and class II molecules using mass spectrometry (MS) technology platforms. Among all the steps in a MS-based immunopeptidomic workflow, sample preparationis critically important for capturing high-quality data of therapeutic relevance. Here, we describe step-by-step instructions to isolate MHC class I and II-associated peptides by immunoaffinity purification from quality control (QC) samples. Our QC samples are MHC class I and class II peptides isolated from mouse (EL4 and A20) and human (JY) cell lines. We thoroughly describe the various reagents and specfic antibodies that are used too isolate MHC-associated peptides from these cell lines, including the steps to verify the beads-binding efficiency of the antibody and the elution efficiency of the MHC-peptide complexes from the beads. QC samples generated using the described protocol can be used to establish and standardize immunopeptidomic workflow, as well as to benchmark new protocols. We anticipate that the visualized protocol provided in this report will represent a great starting point for any non-expert in addition to foster the instra- and inter-laboratory reproducibility of the sample preparation procedure in immunopeptidomics.

2021-12-07 | PXD028633 | Pride

A complete peptidome workflow for neoantigen identification and validation by mass spectrometry-based immunopeptidomics

Project description:We proposed a complete workflow for neoantigen identification and validation based solely on MS immunopeptidomics.We first developed a new Neo DiscoveryTM immunopeptidome enrichment Kit, which can be used for HLA peptide purification from a small amount of biopsied tissue as low as 18mg. To achieve high sensitivity with such a low amount of sample, we leveraged the power of deep learning and a massive amount of MS-based immunopeptidomics data to build DeepNovo-HLA, a de novo sequencing model specialized for HLA peptides. We also developed DeepImmu, a personalized model for immunogenicity prediction based on the central tolerance of T cells, i.e. the positive and negative selection of T cells in an individual patient.

2024-05-04 | PXD046370 | Pride

Study Samples Dendritic Cell MHC II presentation by LC-MSMS

Project description:MAPPs data was used to construct an artificial neural network (ANN) model for MHC class II antigen presentation. Using Infliximab and Rituximab, the model demonstrated an unprecedented performance for predicting MAPPs and CD4 T cell epitopes, complementing results from MAPPs assays and outperforming conventional prediction models trained on binding affinity data.

2020-06-24 | PXD018303 | Pride

Immunopeptidomics identification of Listeria monocytogenes T cell epitopes in mice

Project description:Listeria monocytogenes is a foodborne intracellular bacterial model pathogen. Protective immunity against Listeria depends on an effective CD8 T-cell responses, but very few T cell epitopes are known in mice as most common animal infection model for listeriosis. To identify epitopes we screened for Listeria epitopes presented in the spleen of infected mice by mass spectrometry-based immunopeptidomics. In between more than 6,000 mouse self-peptides presented on MHC Class I molecules, we detected 26 Listeria peptides from 25 different bacterial proteins, including previously reported antigens. Bacterial immunopeptides with confirmed fragmentation spectra were further tested for their potential to CD8 T cells, revealing VTYNYINI from the putative cell wall surface anchor family protein LMON_0576 as a novel bona fide peptide epitope. Despite its high biological potency in a prime boost model, this epitope did not protect against challenge infection but can be used as a research tool to probe CD8 T cell responses in mouse models of Listeria infection. Our results demonstrate the power of immunopeptidomics for bacterial antigen identification but highlight the need for in-depth immune characterization for vaccine candidate selection.

2024-08-13 | PXD047750 | Pride

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients

Project description:Natalizumab (NZM), a humanized monoclonal IgG4 antibody to α4 integrins, is used to treat patients with relapsing-remitting multiple sclerosis (MS), but in about 6% of the cases persistent neutralizing anti-drug antibodies (ADAs) are induced leading to therapy discontinuation. To understand the basis of the ADA response and the mechanism of ADA-mediated neutralization, we performed an in-depth analysis of the B and T cell responses in two patients. By characterizing a large panel of NZM-specific monoclonal antibodies, we found that, in both patients, the response was polyclonal and targeted different epitopes of the NZM idiotype. The neutralizing activity was acquired through somatic mutations and correlated with a slow dissociation rate, a finding that was supported by structural data. Interestingly, in both patients, the analysis of the CD4+ T cell response, combined with mass spectrometry-based peptidomics, revealed a single immunodominant T cell epitope spanning the FR2-CDR2 region of the NZM light chain. Moreover, a CDR2-modified version of NZM was not recognized by T cells, while retaining binding to α4 integrins. Collectively, our integrated analysis identifies the basis of T-B collaboration that leads to ADA-mediated therapeutic resistance and delineates an approach to design novel deimmunized antibodies for autoimmune disease and cancer treatment.

2019-10-10 | PXD013599 | Pride

Deciphering and predicting CD4+ T cell immunodominance of Influenza virus hemagglutinin

Project description:The importance of CD4+ T helper (Th) cells is well appreciated in view of their essential role in the elicitation of antibody and cytotoxic T cell responses. However, the mechanisms that determine the selection of immunodominant epitopes within complex protein antigens remain elusive. Here, we used ex vivo stimulation of memory T cells and screening of naïve and memory T cell libraries, combined with T cell cloning and TCR sequencing, to dissect the human naïve and memory CD4+ T cell repertoire against the influenza pandemic H1 hemagglutinin (H1-HA). We found that naïve CD4+ T cells have a broad repertoire, being able to recognize naturally processed as well as cryptic peptides spanning the whole H1-HA sequence. In contrast, memory Th cells were primarily directed against just a few immunodominant peptides that were readily detected by mass spectrometry-based MHC-II peptidomics and predicted by structural accessibility analysis. Collectively, these findings reveal the presence of a broad repertoire of naïve T cells specific for cryptic H1-HA peptides, and demonstrate that antigen processing represents a major constraint determining immunodominance.

2020-06-29 | PXD018151 | Pride

T1D B lymphocyte cell line Immunopeptidome

Project description:HLA-I and HLA-II immunopeptidome of B cells from healthy control and Type 1 diabetics sharing similar HLA alleles.

2022-02-14 | PXD026184 | Pride

The majority of viral peptides displayed on class I MHC are immunogenic during infection

Project description:CD8+ T cells are essential effectors in anti-viral immunity, recognising short virus-derived peptides presented by MHC class I (pMHCI) on the surface of infected cells. However, the fraction of viral pMHCI on infected cells that are immunogenic has not been shown for any virus. To approach this fundamental question, we used peptide sequencing by high-resolution mass spectrometry to identify nearly 200 vaccinia virus pMHCI presented on infected mouse cells. Next, we screened each peptide for immunogenicity in multiple virus-infected mice, revealing a wide range of immunogenicities. A surprisingly high fraction (>80%) of pMHCI were immunogenic at least one infected animal and around half of these were dominant, which we define as being immunogenic across more than half of the mice screened. The high number of peptides found to be immunogenic and the variability in immunogenicity across mice give us new insight into the specificity of anti-viral CD8+ T cell responses.

2019-01-23 | PXD010811 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data